Eli Lilly

Deal gives Lilly access to Merida’s precision technology targeting disease-causing antibodies

Available in India in 40 mg, 80 mg, 120 mg and 160 mg tablet strengths; administered orally twice daily

The shift reflects intensifying demand for metabolic therapies and growing logistics risk, signaling a structural move toward…

The approval allows a simplified once-monthly 200 mg maintenance dose of Omvoh (mirikizumab-mrkz) for adults with moderately to…

Eli Lilly highlights findings from two late-stage trials demonstrating orforglipron’s effectiveness in improving blood sugar…

The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing healthcare…

Seven out of the top 20 companies registered over 10 per cent YoY revenue growth from 2023 to 2024

The Obesity Gurukul program will aim to offer a structured and immersive learning experience for over 20,000 healthcare…

Eli Lilly’s clinical data with orforglipron in patients with diabetes supports the drug’s potential as an obesity treatment, as…

Doctors have warned of the risk of overuse and misuse, cautioning that patients will see such medications as an easy, quick fix,…